Sleep apnea and heart disease [3]

New England Journal of Medicine

Volumn 354, Issue 10, 2006, Pages 1086-1087

  Zheng, Haoyi ^a   Zhan, Huichun ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN; BIOLOGICAL MARKER; CORBADRINE;

CENTRAL SLEEP APNEA SYNDROME; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HEART DISEASE; HEART FAILURE; HUMAN; LETTER; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SURVIVAL RATE; ARTIFICIAL VENTILATION; METHODOLOGY; MORTALITY; NOTE; BLOOD; EPIDEMIOLOGY; CARDIOMEGALY; CEREBROVASCULAR ACCIDENT; HEART VENTRICLE FUNCTION; RISK FACTOR; SLEEP APNEA SYNDROME; CARDIOVASCULAR DISEASE;

CONTINUOUS POSITIVE AIRWAY PRESSURE; HEART FAILURE, CONGESTIVE; HUMANS; RESPIRATION, ARTIFICIAL; SLEEP APNEA, CENTRAL; BIOLOGICAL MARKERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); NORDEFRIN; SURVIVAL RATE; CARDIOMEGALY; CEREBROVASCULAR ACCIDENT; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; VENTRICULAR DYSFUNCTION; CARDIOVASCULAR DISEASES;

EID: 33644817695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053389     Document Type: Letter

References (3)

1. Bristow MR, Krause-Steinrauf H, Nuzzo R, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-Blocker Evaluation of Survival Trial. Circulation 2004;110:1437-42.
2. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
3. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.